跳转至内容
Merck
CN

Y0000100

奥芬那君 盐酸盐

European Pharmacopoeia (EP) Reference Standard

别名:

β-二甲基氨基乙基-2-甲基二苯甲醚 盐酸盐, N,N-二甲基-2-(2-甲基二苯甲基氧基)乙胺 盐酸盐, 邻甲苯海明 盐酸盐

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C18H23NO · HCl
化学文摘社编号:
分子量:
305.84
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
3745818
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

奥芬那君 盐酸盐, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C18H23NO.ClH/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;/h4-12,18H,13-14H2,1-3H3;1H

SMILES string

Cl.CN(C)CCOC(c1ccccc1)c2ccccc2C

InChI key

UQZKYYIKWZOKKD-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

orphenadrine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

正在寻找类似产品? 访问 产品对比指南

Other Notes

Sales restrictions may apply.

Biochem/physiol Actions

毒蕈碱型受体拮抗剂;H1 组胺受体拮抗剂;肌肉松弛剂。据报道,奥芬那君还可抑制去甲肾上素转运蛋白并且阻塞 NMDA 受体离子通道。

Application

Orphenadrine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jean-François Desaphy et al.
Experimental neurology, 255, 96-102 (2014-03-13)
Although the sodium channel blocker mexiletine is considered the first-line drug in myotonia, some patients experiment adverse effects, while others do not gain any benefit. Other antimyotonic drugs are thus needed to offer mexiletine alternatives. In the present study, we

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持